Big **Idea** CONNECTpreneur

VIRTUAL ROCKET PITCH + POWER NETWORKING

25 JULY IIAM - IPM EDT

CONNECTPRENEUR.ORG

AGENDA

<mark>11:00 - 11:05 АМ</mark> VIRTUAL NETWORKING

11:05 - 11:15 АМ WELCOME & INTRODUCTIONS

TIEN WONG, Founder and Host, CONNECTpreneur Community
SKYLAR RALLISON, Community Manager, CONNECTpreneur

11:15 - 12:00 РМ ROCKET PITCH SESSION

Companies will be introduced by: - SARA CLASPER, Associate Attorney, NEXT powered by Shulman Rogers - MARK HAAS, CEO, AEG

12:00 - 1:00 PM PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

CONNECTPRENEUR.ORG

PRESENTING COMPANIES



Alphyn Biologics, Inc. - Neal Koller

CoupletCare Couplet Care - Stacie McEntyre

FIN**ALYTICS.AI**



Finalytics.ai - Craig McLaughlin

📥 Hedonia Hedonia USA - Gary Schwartz



INTERACTOME BIO

Interactome Bio - Adam Koster



Odyssey Wellness - Scott Frohman



PloomSocial PloomSocial - Cary Carlton



ransradial technologies Transradial Technologies - Randy Hubbell

U-Credit U-Credit - Kevin McNulty

SPEAKERS



TIEN WONG, CEO, OPUS8, INC. @tienwong

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.



Breakthrough Drug of Choice for Atopic Dermatitis (Eczema)

Multi-Target Therapeutics™ A New Class of Drugs More Powerful Therapeutics

MANAGEMENT TEAM

- Neal Koller Chairman & CEO President & CEO, Board of Directors, life science businesses, last exit at 16x; Sr. Exec. Wyeth
- Steven Pentelnik President P&G Exec. managed \$1B early tech portfolio, global manager \$750M Beauty Care Products
- Gary Pekoe, PhD Chief Scientific Officer Director for several multinational pharma companies, led development & approval of 1st & market leading topical antibiotic Bactroban®, lead clinical trial protocol writer for Keytruda®, 20 years clinical and regulatory adviser to pharma
- Jazmyne Mink Regulatory Affairs Manager 8 years' experience with Alphyn's AB-101

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab Emery Pharma - Chemistry & Microbiology Lab World Class Ethnobotanist World Class Botanical Chemistry & Analytics Lab DDL - Formulation and Manufacture PCCA - Formulation and Manufacture Multiple Geo-local Agri Partners TagOne - Supply Chain Management Accelagen - Regulatory and Clinical Trials (AUS) Symbio - Regulatory and Clinical Trials (US, EU) DLA Piper - IP and Legal Worldwide EisnerAmper - Finance and Tax (US) Artus GmbH - Finance and Tax (EU) RDI Partners - Finance and Tax (Australia)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD

- Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ Peter Coderre
- FDA IND & NDA Microbiology Reviewer (retired) Scientific Advisory Board, CARB-X (BARDA, NIAID, NIH) Antimicrobial Regulatory Consulting LLC
- Patric Lundberg, PhD Past Associate Prof, Microbiology/Molecular Cell Biology Eastern Virginia Medical School

Shekhar Mitra, PhD Sr VP, Global Innovation, Procter & Gamble (retired) President, InnoPreneur, LLC

FUNDING TO DATE

Founders	\$870 K (not capitalized)
Seed	\$ 1.1 M (Convertible Note)
Pre-equity	\$ 2.5 M (Convertible Note)
Series A	\$ 5.5 M (Series A)
Non-dilutive	\$ 1.9 M

FINANCING OPEN & MILESTONES

Series B \$18.0 M; \$7M raised

Lead Investor in place, diligence available Complete Phase 2b AD Infected Trial - FUNDED Complete 4x increase drug raw material - FUNDED Complete Phase 2b AD Standard Trial Complete 2nd drug Phase 2 Trial (EB - Orphan Drug)

COMPANY OVERVIEW

Alphyn is using its zabalafin (AB-101) drug platform to develop dermatological therapeutics with fewer side effects, greater patient tolerability and that are more effective, initially for Atopic Dermatitis (AD), and following for Epidermolysis Bullosa (EB). Zabalafin is a new class of drugs named Multi-Target Therapeutics™ providing unique multiple mechanisms of action from multiple bioactive compounds for multiple ways to treat an individual disease, to be more effective, and multiple diseases that can be treated. After only 3½ years of operation Alphyn's 1st drug candidate, topical zabalafin hydrogel, completed 2 Phase 2a clinical trials in AD confirming faster path to regulatory approval in the huge AD commercial opportunity. Clinical results better than competitive drugs point to "drug of choice" for this vast \$118 Billion market ⁵ with potential 800 million patient population ¹.

THE PROBLEMS IN TREATING AD

- 60.5% of adults report severe itch
- 67% of children and 33% of adults report significant sleep disturbances, poor quality of life²
- 55 % report inadequate disease control²
- 8.3-year life reduction with hospitalizations primarily due to AD bacteria-associated problems ³

TWO SUCCESSFUL PHASE 2a CLINCIAL TRIALS: ZABALAFIN ADVANTAGES

- Most important itch superior to competition
- Only AD drug to directly treat itch and the critical Bacteria Component of AD
- 90% of patients report significant improvement in Quality of Life •
- 35% better reduction in inflammation versus dominate market leader (IGA)
- Side effect reduction and patient tolerability superior to competition
- Strong safety data resulted in: Waiver of Phase 1 clinical trial; Phase 2 clinical trials start age 2 •
- Clinical results point to 'Drug of Choice' for AD





MULTIPLE MARKET PROTECTION STRATEGIES

- Patent exclusivity potential to 2042: US & Worldwide, Composition of Matter, Methods of Use
- Regulatory exclusivity possible: 10 years USA, 8 years Europe & Japan
- No FDA generic drug competition possibility

Acquired / Licensed

Kyowa Kirin (by Amgen)

Proteologix (by J&J)

Kymab (by Sanofi)

Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory •

VAST AND GROWING AD MARKET

Drug (Company)	Time on Market	Annualized Sales ⁴	Estimated Patient # 5
Dupixent [®] (Sanofi)	4 years	\$7 Billion	~ 270,000
Opzelura [®] (Incyte)	2 years	\$380 Million	~ 103,500

AD STRONG COMPARABLE EXIT DEALS

ones <u>Exit Stage</u>
nes Pre-clinical
Phase 2 clinical trial
Phase 2 clinical trial

CoupletCare

Company Overview: Couplet Care, Inc. is transforming the postnatal experience in hospitals and birthing centers with an innovative medical infant bassinet – a University of North Carolina spin-out, 510(k) Exempt, Class II Medical Device, with patents in 7 countries, exclusive IP, strong interest from hospitals, and will be for sale in the US Q3 '24.

Problem: The global standard on postnatal units is "rooming-in" – an infant remains in the hospital room with the mom – leading to long-term positive health outcomes. But outdated bassinets are barriers to accessing the infant, leading to infant drops/injuries, infant suffocation, maternal pain and distress, an inability to establish breastfeeding, nursing inefficiencies, and hospital risk at a time that should be joyful for all.

Solution: Couplet Care BassinetTM is the ONLY bassinet that allows the mom to 100% independently access and transfer the infant without the need of a second person. Extensive research and user-need surveys informed the design to achieve infant safety, maternal access and comfort, and nursing efficiency.

Couplet Care, Inc.

www.coupletcare.com <u>Stacie@CoupletCare.com</u> (919) 597-0296

Funding

Total seeking: \$750K Convertible Note Bridge Round: Remaining \$350k Series A - \$2 million Q1 '25 Total raised to date: \$2.5M non-dilutive funding (NIH+) \$1.4M investments

Financials

Revenue: Pre-revenue Cash Flow in 2025

Team

CEO: Stacie McEntyre, 35 years in healthcare, visioned, built and led a \$65M healthcare system. Founder: Dr. Kristin Tully, internationally recognized University of North Carolina maternal-infant health & safety expert Board of Directors: Don Holzworth, Chair; Jan Davis; Nikin Shah Board of Advisors: Dr. Carl Seashore, Dr. Andrea Braden, Ty Hagler

Conclusion: Hospitals must update equipment to reduce risks. We have a clear commercialization pathway leading to a strong return for investors. while transforming lives. **Technology:** Couplet Care BassinetTM was designed by Dr. Kristin Tully, maternal infant expert at the University of NC, and was backed with extensive research - *8 published peer-reviewed scientific articles* authored by Dr. Tully supporting the development of the Couplet Care Bassinet, and with research by Drs. Alison Stuebe, Carl Seashore, and Catherine Sullivan with the *Carolina Global Breastfeeding Institute*. Input from 3,500 new moms and healthcare workers to address the serious gap between the benefits of "rooming-in" and the detriments of old-style bassinets. Couplet Care's NIH usability pilot study showed statistical significance in nursing efficiency, with a 73% reduction in mom calls to the nurse for non-medical reason - meaningful in today's environment of healthcare staffing shortages.

IP/Defensibility: Couplet Care, Inc. holds the IP in an exclusive license agreement with the UNC Department of Technology Commercialization. Freedom to Operate work is completed. Patents in 7 countries. Continuation claims & new patent claims filled 3Q23.

Competition/Competitive Advantage: The Couplet Care BassinetTM uniquely allows the mom to **100% independently access** the infant. Standard bassinet, the Stryker Nara, and the Halo Bassinest© are common competitive models, but don't offer full **independent access**.

Market Size/Customers: \$1.4B Total Addressable Market (2019 OECD International Healthcare Statistics). Target customers include women's hospitals and birthing centers, initially in the US, but ultimately in 6 EU, Canada, Japan, China, Brazil, and Australia and beyond.

Business Model: \$4500 - 6,000 projected MSRP; ~50 - 60% margins expected at scale in 2026. Revenue through hospital Operations/CAPEX budgets, grants, auxiliary funds, or lease financing programs.

Traction: NIH Phase II Study being conducted at Johns Hopkins University. Will be "for sale in the US" by Q3 '24. Pre-production units are expected in 4Q24, with the first 600 production units delivered to hospitals beginning 2Q25.

FINALYTICS.A

Value Proposition: Finalytics.ai enables banks and credit unions to personalize the digital experience using AI to drive new customer acquisition, increase wallet share, and improve satisfaction.

Company Background:

Finalytics.ai was founded in 2021, and has been self-funded to date, growing to over \$1.5m in ARR with 15 customers.

Leadership Team:

The senior management team at Finalytics.ai is comprised of seasoned digital banking veterans with decades of combined experience in banking:

Craig McLaughlin: CEO & Co-founder, with 25 years of banking experience. Mark Ryan: CAO & Co-founder, with 25 years of banking data experience. John McKenna: VP of Sales, with 31 years of banking sale experience. Scott Barnard: CTO, with 20 years of development and UX experience. Baron Conway: Chief Strategy Officer, with 25 years digital finance experience.

Products/Services:

Finalytics.ai is our flagship product – a SaaS platform. It delivers a holistic customer experience bridging the gap across online banking, CRM, and online account origination systems, enabling 'Segment-of-One' personalized experiences across all digital channels for banks.

Technologies/Special Know-How:

We know banking and have deep expertise in data analytics. Our experience is in solving the challenges community banks face in navigating digital transformation. We recognized the market whitespace for personalization and set out to fill it, deliver truly omni-channel customer experiences.

Market:

Our market is initially the 5000 banks and 5000 credit unions in North America. In the medium term we will expand to insurance and investment services.

Distribution Channels:

We sell direct and through partners.

Competition:

We compete against a series of technology competitors. Our strength is two pronged: (1) Industry specialization/integrations and (2) Speed to deployment with integration built into the offering.

Financial Projections (Unaudited):

		2022	2023	2024	2025	2026
	Revenue	300,000	1,324,908	\$ 3,000,000.00	\$4,500,000	\$6,000,000
-	CDIT	(1 205 022 00)	(10,485,00)			
	EBIT	(1,295,033.00)	(19,485.00)			

Quick Facts

Company Name: Finalytics.ai

CEO: Craig McLaughlin

Address: 1825 S. Grant St San Mateo CA 94402

Phone: 415-806-3820 Email: craig@finalytics.ai Website: www.finalytics.ai

Industry: Financial Servies

Domain: Banking

Bank: Chase

Law Firm: Mannat

Patent Estate:

Number of Employees: 12

Amount of Financing Sought: \$5m

Current Investors: Bootstrapped

Use of Funds: Product development and sales/marketing.

Auditor: TBD

EXECUTIVE SUMMARY

VALUE PROPOSITION

Hedonia is a revolutionary product, an all-natural, first-of-its-kind medical food. It is specially formulated to address the unique nutritional needs of people suffering from depression, without the need for a prescription and without the side effect profile associated with pharmacological agents.

Hedonia[™] is not a drug. It is not a supplement. It is a unique patented 3-in-1 product classified as a medical food. Hedonia is specifically formulated to address the unique nutritional imbalances and or deficiencies of people with depression, which cannot be managed by an ordinary diet alone. The nutrients (Omega-3, SAMe,



edonia

Get more out of your depression therapy..

and L-methylfolate) occur naturally in your body but may be out of balance in your brain if you suffer from depression. Hedonia works by raising the levels of these critical nutrients to normal, healthy levels. Medical foods have been used since the 1950s. They have been developed for many diseases, such as Crohn's, ulcerative colitis, gastroesophageal reflux, insomnia, Alzheimer's, and Parkinson's. Examples of Medical foods include Pedialyte, Ensure, Glucerna, and Pulmocare.

LEADERSHIP TEAM

Alexander Vuckovic, M.D. Founder, Inventor & Chief Scientific Officer

Dany Sfeir, Chief Executive Officer

Bengt Persson, Chief Operating Officer

Shepard Kramer, Chief Marketing Officer

SCIENCE BOARD OF ADVISORS

Alexander Vuckovic, MD Founder & CSO

Dr. Joseph Firth, PhD University of Manchester

Derek Tobin, PhD Clinical Science Manger Epax Norway

Prof. Jerome Sarris, PhD Psychae Institute

COMPANY BACKGROUND

Hedonia USA, Inc. was incorporated in January 2021 in the State of Delaware. The company was founded by Dr. Alex Vuckovic, a Harvard Medical School Psychiatrist and Psycopharmacologist, based upon his over 40 years of treating patients with depression as well as substantial published research by many practitioners.

COMPETITION

There has never been a product like Hedonia on the market and as we sit here today there is no competition and will not be for a long time because of our patent protection.



ADDRESSABLE MARKET

The World Health Organization (WHO) estimates there are one billion people globally suffering from depression, or about 1 in every 5 people. In the United States, 31 million people have mild to intermittent depression. At an average cost of \$2,200 for a one-year supply of Hedonia would be a \$6.82 billion in market just in the USA.

DISTRIBUTION CHANNELS



We intend to launch Hedonia in mid Q3 2024 and will initially be marketed as medical food and sold as direct to consumer (D2C) via our website. After the launch of the medical food product, we will market Hedonia selling to select retailers. Within 2 years we will execute our full retail strategy, working with pharmacies and large retailers to sell Hedonia both as a medical food and in alternate formulation with a family of supplements to address the 80 million USA residents who take supplements daily.



Hedonia has patents that protect the product through 2037 both domestically and internationally as well as in an supplement version. In addition, the company has a patent on its special dual capsule delivery system.

ASK

Hedonia USA, Inc. has raised \$2.9 million to date both in seed capital and a Series A round. Currently, we are seeking \$10 million in Series B financing. The capital will be used as follows:

Marketing and Media	52%
Manufacturing and raw material	22%
Talent acquisition	11%
Research & development	15%
Total	100%



Industry: Biopharmaceuticals

Number of Employees: 7

Amount of Financing Sought: \$2.5M

E Company Background:

Company founded on several decades of Extracellular Vesicle (EV) therapeutic research with focus in Neurology, Cardiovascular and Aesthetic markets. Over the last 5 years, we have developed proven superior EV and exosome products and advanced bioprocesses providing near-term and long-term value.

(p) Products/Services:

Our superior EV and Exosome products have been validated through *in vivo* studies and industry standard biomarkers. Our patented bioprocess is under development and prototype, with sourcing, isolation, purification, and characterization validated internally. Our platform resolves major challenges in the field including broad drug compatibility, immune silence, as well as rapid distribution and retention, expanding the therapeutic index.

A Market:

Our initial target market will focus on the fast-growing aesthetic medical spas, plastic surgeons and dermatologists using our products to rejuvenate the skin – Cosmetic Serum (\$3B TAM). Additionally, our lead FDA program is focused on Neurology (\$6B TAM) and Cardiology (\$15B TAM) through our strong pipeline from our Henry Ford partnership and our RNA Therapeutics development option with Oxford.

Value Proposition:

Next generation superior EV products and IP protected manufacturing bioprocess targeting the rapid growth and expansion of EV applications. Q3 2024 commercialization of IB's superior exosome products for the Aesthetics market. Strong regulatory property pipeline of FDA IND filings in Neurology and Cardiovascular via novel enzymatic glycolytic mediated RNA delivery via Extracellular Vesicles in Q4 2024.

Technologies:

Combining our IP-protected bioprocess with global clinician scientists to execute our inlicensed asset portfolio that is scalable, reproducible, and circumvents current issues in the cell therapy domain limiting the success of preclinical and clinical readouts.

IB Targeting the Exosome market growth driven by increasing clinical applications

\$168M+ Market	34% CAGR 2022-	\$2.27B+ Market
Size 2021	2030 🔪	Size
(A)	(E)	2030 (P)

(Aesthetic, Dermatology,

Anti-inflammatory, Regenerative Medicine, etc.)

(a) Sales & Distribution: We currently have converted customers for our regenerative dermatology products and project \$3M+ sales in fiscal 2024–25, growing to \$10M+ in fiscal 2026–27.

	Financial	(Unaudited)	2023	2024	2025	2026
핉	Financial Projections	Revenue	\$252,500	\$3,615,000	\$7,750,000	\$10,625,000
	rojections	Net Income	- \$329,905	\$261,000	\$776,000	\$1,366,250

O Capital Raise:

\$2.5M Seed funding to complete near term aesthetic product commercialization and manufacturing scale. 2-year funding to complete IND application in H1 2025

E Leadership Team:

Adam Koster, CEO, Co-Founder Matthew Peterson, MD, MBA, Chief Medical Officer

Frederick Naftolin, MD, PhD, Co-Founder James Secrest, MA, DC, Director of Manufacturing

Contact: Adam Koster, CEO, Co-Founder Phone: (773) 919-5430 Email: <u>invest@interactomebio.com</u> Website: <u>www.interactomebio.com</u>

Use of Funds:


Production/Operational Cost, Bioprocess prototype development, Master Control execution, production batch execution, product marketing, and IND regulatory fees.

Company Name: Interactome Biotherapeutics Inc Location: 401 W Mosel Ave Kalamazoo, MI 49004 Bank: Chase Life Sciences Connect Law Firm: Dykema Law

Medical & Scientific Advisory Board:


Michael Chopp, PhD Chair, Henry Ford Neuro Kenneth Witwer, PhD ISEV President, John's Hopkins

Shawn Tierney, DC, RMSK Nerve Hydrodissection Expert Dhanu Gupta, PhD Oxford University



ODYSSEY is a leader in the Natural Channel Ready-to-Drink (RTD) energy beverage market that specializes in cognitive and mood-boosting performance - disrupting the stagnant, outdated energy drink category by using an innovative proprietary blend of high potency Lion's Mane, Cordyceps, and other ingredients to develop these effects. We use no artificial sweeteners or preservatives and have exceptional flavor.

- Product Launch June 2021
- 17.8M Fully Diluted LLC Units Prior to Ongoing Capital Raise at \$3 Per Convertible Unit
- Over \$18M Raised to Date
- 26 Employees
- HQ in Fort Lauderdale, FL





ODYSSEY

Our original product launched into the Natural Channel in January 2022. Only 85mg of caffeine with high potency Lion's Mane and Cordyceps, for cognitive and moodboosting performance. This product has some of the highest velocities in the Natural beverage category. - ODYSSEY is pioneering a new natural functional beverage category that delivers mental clarity, energy and hydration.

• ODYSSEY was presented 2024 VITY Award for best Functional Beverage in Sports Nutrition Category.

 Recently authorized to stock all ODESSEY product SKUs in all Target[®] stores nationwide.

- Recently authorized to stock all ODESSEY 222 SKUs in all 7 Eleven stores from Orlando to the Florida Keys as well as all Kroger grocery stores in Ohio.

• ODYSSEY ranked #1 in sales in Natural Channel by both INFRA and National Co+op Grocers (SPINS 12 week read ending 6/16/2024).

 Posted record Q2 2024 AMAZON sales (\$810K; up 246%) and AMAZON subscribers (3,189; up 276%).

• Mordor Intelligence estimates the Ready-to-Drink Beverages Market at \$361B in 2024 and is expected to reach \$456B by 2029 (4.8% CAGR).

 Target markets: Gen Z (18-24), Millennial (25-40), Gamers, Soccer Moms, Athletes and Golfers.

ODYSSEY 222 ACCOMPANY ENERGY + FOCUS SARRELING DIMENSION CONSTANTS CONSTANTS

E DEVAN

ODYSSEY 222

Ideal for MULO / Convenience Stores. It has 222mg of caffeine plus high potency Lion's Mane and Cordyceps. This gives sustainable energy and clarity over a longer period without the crash and jitters.

<section-header>







KEY RETAILERS Sold in Over 8,000 Stores Nationwide



ODYSSEY REVIVE

Was formulated in mind for music festival goers and night life. Utilizing zero caffeine, with electrolytes, magnesium, zinc, vitamin C, and high potency Lion's Mane and Cordyceps. This functional product is winning throughout many channels.



Value Proposition: PloomSocial revolutionizes the fundraising experience by combining the power of video storytelling with the efficiency of a comprehensive, secure platform. Our unique approach provides several key benefits:

1. Engagement Through Storytelling: We enable fundraisers to create compelling, episodic video content that connects donors emotionally to their cause, fostering deeper engagement and long-term support.

2. Transparency and Trust: By offering real-time updates and showcasing the tangible impact of contributions, PloomSocial builds transparency and trust between fundraisers and donors.

3. Ease of Use: Our platform is designed for simplicity, allowing users to easily create campaigns, share them with their communities, and track progress. The intuitive interface ensures that anyone can navigate and use the platform effectively.

4. Secure Transactions: PloomSocial is fully KYC compliant and integrates robust AML features, ensuring that all transactions are secure. We utilize Stripe for seamless and reliable payment processing.

Company Background:

PloomSocial, founded by Cary Carlton and Chris Bobo in 2022, revolutionizes fundraising by merging video storytelling with social networking. Our platform enhances donor engagement and transparency, enabling fundraisers to connect directly with their communities. Serving a wide range of users, from nonprofits to personal campaigns, PloomSocial stands out by turning fundraising into a dynamic, impactful social experience.

Leadership Team:

- 1. Cary Carlton; 20+ years software sales leadership
- 2. Chris Bobo: 20+ years software sales leadership
- 3. Quan Tran: 20+ YEARS CTO leadership
- 4. Kevin Harrington: Advisory Board Member and Investor
- 5. Brandon T Adams: Advisory Board Member and Investor
- 6. Randy Lewis: Advisory Board, COO of REIT Mutual Fund- Founder

Products/Services:

- 1. Fully KYC compliant and AML-integrated platform
- 2. Episodic Video Storytelling
- 3. Ad Revenue Sharing, SAS Premium Services
- 4. Social Network Introducing- providing multiple donor windows
- 5.PloomSocial donates 0.5% of its platform revenue to our charitable partners.

Technologies/Special Know-How: N/A

.,..

Market:

Non-Profit Organizations

Community and Educational Groups: Schools, sports teams, and local organizations **Individual Fundraisers**: People raising money for personal causes, medical expenses PloomSocial operates on a transaction-based revenue model, charging an 8% percentage fee on each donation processed through our platform. We offer premium services and features for fundraisers who seek advanced tools and personalized support. TAM=265B/SAM=32b SOM=2.17B

Distribution Channels: *N/A* Competition:

- 1. GoFundMe
- 2. GiveButter
- 3. Instagram
- 4. Facebook
- 5. Donor Box

Financial Projections (Unaudited):

	2024	2025	2026	2027	2028
Revenue	800,000	4,290,000	13,000,000	26,000,000	50,000,000
EBIT (dollars	350,000	1,501,500	4,500,000	8.320,000	15,000,000
in thousands)					

Quick Facts Company Name: PloomSocial

Contact: Cary Carlton

Address:2211 Michelson Drive Irvine CA 92621 Phone:949-826-1321 Email:cary@ploomsocial.com Website:ploomsocial.com

Industry: FinTech

Domain:

Bank: Banc of California

Law Firm: Perkins & Coie

Patent Estate:

Number of Employees: 5

Leadership Team: 4

Amount of Financing Sought: 3,000,000

Current Investors: 25

Use of Funds: Technology enhancements. User traction. Brand Awareness

Auditor:N/a

Executive Summary, July 2024

Value Proposition

The SĀPH device is a radial artery closure system that provides a unique method of creating hemostasis following a catheterization procedure. This patent-pending technology offers investors the opportunity to engage with a truly new standard of care in one of the fastest growing markets in the interventional cardiovascular space.

Company Background:


Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device. The device is designed to offer a "fast, safe, and easy-to-use" closure solution for radial artery punctures created during a full range of interventional procedures including cardiac catheterization, percutaneous coronary revascularization, and peripheral angiography/revascularization. Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transluminal Technologies, Inc.

Leadership Team: Five exits worth over \$1B – Multiple Acquisitions) & over 100+ years of medical technologies experience

- Randy Hubbell, CEO Over 30 years of medical device, biotechnology and pharmaceutical industry experience at both large multinationals, such as Boston Scientific Corporation and Johnson & Johnson, and four start-ups that led to three exits, including Cardiva Medical, a vascular closure company that was sold to Haemonetics for \$500M. Was CEO for Carmell Corp (NASDAQ: CTCX) from 2016 to 2023, a journey that started with a spin out of Carnegie Mellon University worth \$6M to a public merger at \$150M.
- Ron Caputo, MD, CMO Dr. Caputo is a practicing interventional cardiologist with over 80 authored/co-authored peer-reviewed publications and a history of successful medical device entrepreneurship, including co-founding Angiolink, Corp which was acquired by Medtronic (NYSE: MDT).
- Stephen Green, President Steve has over 40 years of medical device design and development that includes over 20 US and Int'l patents and multiple regulatory product approvals.

Product & Technology

SĀPH (Suction Activated Patent Hemostasis) – Designed to address the growing market of procedures performed using radial artery access, the SĀPH device uniquely closes the arterial puncture by expanding the artery to create compression with the artery puncture site and the surrounding tissue rather than the traditional method of compressing the artery with a tourniquet around the wrist. The **SĀPH** device achieves a lower rate of radial artery occlusion, a more comfortable patient experience, and importantly, reduces the workload for recovery staff, (i.e. no intermittent patient monitoring is necessary). First in man testing (17 patients) has been successfully completed. This technology is also well suited to transpedal and distal radial arterial access and potentially femoral venous procedures.



Intellectual Property

A non-provisional US patent application (August 2022) as well as a continuation-in-part has been filed with the USPTO. A full runway of patent life remains.

Distribution Channels

Expected sales channel through a large multi-national strategic via acquisition with existing sales & marketing infrastructure in this space.

Competition

The current standard of care, conventional compression, utilizes a tourniquet-band and inflatable bladder which compresses and flattens the wrist and artery, restricting blood flow, and creating significant discomfort for the patient. Terumo Corporation currently holds a predominant market share (>70%) in this conventional compression category. Many large companies, such as Boston Scientific, Medtronic, Abbott, Merit Medical and Teleflex have significant presence in the hospital where the procedures occur and have little or no radial access vascular closure sales.

Financial Projections (Unaudited)

Financiai i roje	cuo	15 (01	iau	uncuj									
In Millions	2	026		2027	2028	2029	2030	2031	2032	2033	2034	2035	2036
Revenue	\$	1.10	\$	3.36	\$ 13.19	\$ 22.04	\$ 30.63	\$ 47.79	\$ 66.15	\$ 94.25	\$ 115.22	\$ 128.14	\$ 141.56

Quick Facts

Company Name: Transradial Technologies, Inc. Contact: Randy Hubbell Address: 2930 E. Genesee St. Syracuse, NY 13224 Phone: (215) 688-6196 Email: Randolphhubbell@hubbellmedtech.com Website: Under construction **Industry**: Medical Device Bank: Pinnacle Law Firm: Jones Walker Patent Estate: Patent Pending Number of Employees: 4 Amount of Financing Sought: \$3M **Current Investors:** Transluminal Technologies, Inc. Use of Funds: 510k registration, observational study, general & administrative



U-Credit

Shaping the future of carbon emissions reduction

A carbon offset is a reduction or removal of emissions of CO2 or other greenhouse gases (GHGs) through a qualified project, typically representing an emission reduction of 1 metric ton of CO2e. Carbon credits or offsets are purchased or traded by businesses or individuals to reduce their carbon intensity emissions.

Carbon Credit Market Concerns

For these markets to work the carbon reduction or offset projects need to be verified and certified to confirm that they meet established criteria, typically calling for manual field work and desk work to establish the credit. However, the current market faces concerns regarding verification and pricing due to the lack of a single governing standard.

The U-Credit Solution

U-Credit provides a solution by automating and simplifying the verification and certification process, ensuring the accuracy and integrity of the data in the process. Using advanced technology like smart contracts and distributed ledger systems, U-Credit tracks and verifies carbon emissions reductions in a tamper-proof manner. This improved legitimacy of the carbon offset increases its value while significantly reducing the cost of the current verification process. Tokenization then allows for easy purchase, sale, and trading of the U-Credits created.

Creating and Verifying Carbon Credits

With the help of AI algorithms, U-Credit can verify the creation of carbon credits by cross-referencing data from various sources such as geolocation, weather reports, usage patterns, system operations, emission permits, and market dynamics. Real-time monitoring allows for ongoing validation of the credits and reduces the need for human intervention in the verification and monitoring process.

Creating Immutable Data Sets

To ensure tamper-proof tracking of carbon emissions reductions and guarantee the integrity of transactions, a distributed ledger system adds an extra layer of security by creating an immutable record of the data stored. Transactions are kept secure and safe as they are verified and validated via the secure DLT platform.

Carbon Credit Tracking

The U-Credit system consists of user onboarding, smart meters, and a distributed ledger database, all working together to create an accountable and transparent history of carbon credit generation and consumption tied to energy generation.

Tokenizing Carbon Credits

Through the DLT, U-Credit tokens can be created to represent NFTs based on the metric tons of CO2e created, the current standard. U-Credit tokens are minted based on data gathered by smart meters with proprietary hardware, or through the pre-sale of credits to fund carbon reductions projects.

Creation of Tradable Credits

The U-Credit tokens represent a store of value backed by the underlying carbon offsets. Thus, the tokens can be used in purchase, sale, or trade for other goods and services, or used as collateral. Once they are applied as an offset, however, the tokens are redeemed and effectively removed from circulation.

U-Credit Facilitates Carbon Reduction

U-Credit opens new opportunities for energy producers and consumers, allowing them to monetize carbon credits more easily. By reducing the cost for carbon credit creation and validation, U-Credit democratizes the carbon market and enables individuals to participate in creating and selling carbon credits, even using carbon credits for purchases of goods and services. U-Credit incentivizes sustainable energy practices resulting in cleaner and more efficient energy solutions and eco-friendly choices.

Transforming Energy Markets

U-Credit has the potential to revolutionize the energy market by creating a common basis between energy sources. Utilizing its Core Technology any sort of energy produced, whether electricity, gaseous fuels (e.g., natural gas, hydrogen), or liquid fuels (diesel, gasoline), can all be automatically converted to a carbon equivalent. Tying the various forms of energy to a carbon value can potentially put them on equal footing, thus providing a cross-reference of value, and allowing for purchase, sale, and trading across energy resources.



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his Chinabased experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at amillineshulmanrogers.com.



AEG @enterprisegrowth

AEG is a "Time Machine" for business leaders. We accelerate development of trust, driving fast and efficient referrals to accelerate business development and growth. We are a values-based membership organization of three communities (1) CEOs of \$20M+ companies in diverse industries, (2) elite advisors in complementary disciplines, and (3) regional centers of influence including economic development, trade associations and media.



MARK HAAS, CEO, AEG @MarkHaas

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.

PRINCE WILLIAM PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

The Prince William County Department of Economic Development and Tourism works hard to create a pro-business, globally-competitive environment that generates new, high-quality, and sustainable job opportunities for our residents and destination-driven attractions for our visitors. The department engages in a broad portfolio of services, partnerships, and strategic alliances to benefit the business community, including small businesses, startups, and entrepreneurs.



MICHELE WEATHERLY, DIRECTOR OF EXISTING BUSINESS AND ENTREPRENEURSHIP, PRINCE WILLIAM COUNTY

Michele Weatherly currently serves as the Director of Existing Business and Entrepreneurship with Prince William County Department of Economic Development and Tourism. Michele is a Washington DC Metro area Business Development professional with a track record of successful leadership in trade associations and economic development. Michele specializes in workforce and business development programs and marketing with a strong network of industry colleagues in the DC metro region and beyond the beltway.

Michele currently serves on the Board of Directors for Virginia Career Works, Committee for Dulles, Virginia Serious Game Institute, and the Career Technical Education Program Advisory Council for Prince William County Schools.

REFRACTION @refractionpt



Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD_Dingman

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."

KEIRETSU



KEIRETSU FORUM @KeiretsuAngels

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.

BALTIMOREANGELS 🔶 THE BALTIMORE ANGELS @baltimoreangels

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.



arind

MARYLAND, US

MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Marylandbased tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.

STARTUP GRIND-COLUMBIA, MD @StartupGrindDC

startup Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.

ANGELS + LIFE.SCI INVESTORS Angels + Life.Sci

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



Investors

GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS @Hoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



RYAN & WETMORE, P.C. @RyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



ENTERPRISE TRANSFORMATION SOLUTIONS INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.

ETS Enterprise Transformation Solutions

July 25 Attendees As of 07 25 24

SPEAKERS			
First Name	Last Name	Title	Company
Tien	Wong	Founder and Host	CONNECTpreneur
Mark	Haas	CEO	AEG
Sara	Clasper	Associate	NEXT powered by Shulman Rogers
PRESENTERS			
First Name	Last Name	Title	Company
Neal	Koller	Chairman and CEO	Alphyn Biologics, Inc.
Stacie	McEntyre	CEO	Couplet Care, Inc.
Craig	McLaughlin	CEO	Finalytics.ai
Gary	Schwartz	CFO	Hedonia USA, Inc.
Adam	Koster	CEO and Co-Founder	Interactome Biotherapeutics
Scott	Frohman	CEO	Odyssey Wellness
Cary	Carlton	CEO and Founder	PloomSocial
Randy	Hubbell	CEO	Transradial Technologies Inc
Kevin	McNulty	Director	U-Credit
ATTENDEES			
First Name	Last Name	Title	Company
Jayashankar	А	Co-founder & CTO	ValueMatrix.ai
Mansur	Abahusayn	President	Glacier Technologies International Inc,.
Cedric	Abou	Engineer	Private
Faith	Abraham	Chief Executive Officer	Volshauz Brands Pvt Ltd
Richard	Adams	CEO Manazian Partana	Hygiene IQ LLC
Michael	Adler	Managing Partner Executive Director	Adler Consulting Strategies LLC
Felix	Agakov	CEO	Pharmatics Celesticus
Kanav Jorge	Aggarwal Aguado	Co-founder & CEO	The Future Co
Udhe	Ahluwalia	Founder/CEO	Riiwards inc.
Malachi	Alexander	Product Designer	Villa Health
Felipe	Anciola	VP Strategic Growth & Investor Relations	Gesture
Joseph	Anders	President	LeoSat Enterprises
Lekan	Anlugbua II	CEO	Leks Energy LLC
Afrozy	ARA	Cofounder	LuminaData
AJ	Attavar	Investor	NPS, Inc
Darrin	Auito	Partner	HEA Law PLLC
Erika	Baez-Grimes	Business Broker Mergers & Acquisitions	Transworld Business Advisors
Dan	Ballin	Chief Executive COO	Ideas Crucible
Ben Ole Henrik	Bamberger Bang-Andreasen	Venture capitalist	Tiber Solutions Avant Bio
SJ	Barakony	Super Connector, Futurist, and Sherpa	Availebio
Yann	Barbarroux	CEO	Otonomi
Jon	Barlow	EcoProjects Manager	Power Alternative LLC
Thomas	Bascom	President	LinkSpace, LLC
Fernando	Batista	COO	InvestUSC
Lincoln	Belitz	CSO	EXtrance
Gus	Bessalel	Author	The Startup Lottery
Marcya	Betts	Trademark Attorney	Darden Betts Strategic IP Counselors
Lauren	Bigelow	CEO	GCN
David	Blair	President	Northern Lights Management Corporation
Colin Randy	Blair Blake	CEO Principal	Sensurance Duncaster Investments
Austin	Bliss	CEO	Sensar Marine US, Inc.
Christopher	Bobo	C00	PloomSocial
Prasad	Bopardikar	Principal	
Chantal	Bouchard	Account Executive	DivNotes Inc.
John	Bracken	COO	Localvest
Cathy	Bradley	CEO	CBE
Jan	Breukers	CEO	First Choice Bio, Inc.
LB	Brittingham	Founder	SCBiz Small Business Growth Accelerator
Zach	Brodsky	Senior Associate	Florida Funders
Sil	Bronder	Opts	NAVF / Clear
	Brown	AD, CMC Operations	Invetx Inc.
Dusty			Strategy Innovators LLC
Douglas	Brown	Patent Agent	
	Brown Brown Buividaitė	CFO CEO	Diamond A Corp VESTIMUS

Alexius Sandra Antonio Robert JaneScott Joe Cary Sue Damian Matilde Hepzel John AC Youjeong Wen Tony Pierre-Jean Nelson Hyde Lloyd Andrew Matthew Natalie Regina Simon Dan Dan Shaniece Albert Jane Jim Vincent Vincent Davis Darren Paramita Marcel Maria Ashish Hastikaben Poorva Lillian Molly Benjamin John Mike Monick Gabriel Chris Radha Cherie Peter Alan Amzi Stephen Jonathan Wael Reginald Brad Maria Matt Herb Herb Kim Caroline Ashley Giovanni Sina Afrina Richard Zach Terry Terry Robert

Makayla

Cabral Cai Canovas Cantrell Cantus Carlin Carlton Carr Carvajal Ibanez Casccella Castro Cataldi Chan Chang Chang Che Cherret Chick Chirindo Choi Cimino Clyke Cohen Collingridge Conlev Corcoran Craigs Crews Crozier Cruz-Youll Darago Darago Darvish Dasburg Debbarman Deer Del Hoyo Deshmukh Devda Dharkar Diaz Dill Dimowo Dinusson Dowdle Ducos Dumv Dunn Duttagupta Edilson Egli Ehrlich Ellington Elliot Elliott ElShamy Emordi Enneking Ermolova Evans Ezrin Ezrin F Fairbank Falvey Farese Faridimehr Fatini Faulkner Fenton Fick Fick Fine Fischer

SD Holdings Plurall AI Business Developer Patent Agent Managing Principal Principal CEO & Founder CEO Scouting & Partnering Junior Associate Investo Independent Consultant CEO Freelancer Senior Manager AVP, Discovery and Early Development CEO **Energy Markets Strategy** CAO Head of Risk CEO Innovation and Business Development Founder | CEO Shaman MD Active Angel Owner Bookkeeping VP of Product Innovation and New Ventures Instructor/Coach Consultant Software Engineer CIO / Founder CIO/Founder CEO CEO **Business Strategist** SEO Content Writer **Executive Vice President** CVP Founder CEO CEO Businesses Entrepreneur Managing Director Founder President Founder Marketing Consultant CTO & Founder Principal Consultant VP, Clinical Affairs CEO/Founder **Executive Director** President Managing Director CEO & Founder Investment Manager President and CEO Wealth Management Advisor CIO Investment Banking Managing Director Mentor CEO & President CEO & President Advisor Sr Associate Principal CEO Co-Founder and CEO Personal Interest CEO IT Director Managing Director CEO **Executive Director** Impact Investing Intern

Chief Business Officer Founder Inspiralia Strategy Innovators LLC ILEX Leadership Associates LLC JonXeone Capital PloomSocial CarrTech Corp Debiopharm International SA Activant Capital hchconsulting Native American Venture Fund / Clear Health Pass Nil Stonebridge Capital AcuraStem VRoad Innovative Solutions Inc. Renault Foil Flyer 1010 Technologies Beige LLC Maryland Department of Commerce Rocktree MgO Construction Materials Inc Eagle Venture Evoto Angels + Life.Sci Investors NJAngels.net Blue Dog Consulting LLC Mindful Growth Print St Jude Trusted Boat Trusted Boat BMAT Clarus Biologics PDCC Marcel Deer Consultancy Rare Gold Music Group Valuebridge Ventures HKD Cancer Immunotherapy Solns Inc Ziva Consulting Wellness peak nutrition LLC gener8tor VA-Africa LTD Wave Forms Med Tech **Circadian Ventures** Serial Disruptors KOLIBRI CD Tech Marketing Nucleix Member Marketplace Inc LGT Capital Partners Ehrlich & Associates,LTD ConcentricDNA Health Innovations, LLC NeuroBright Ejtemai Family Office VARONA.LLC Merrill Lynch HTLF Weild & Co. SCORE Potomac Business Group Potomac Business Group Initiate DAB Holdings LLC Webidoo Enerytics Personal Interest IQ Exchange LLC Flint Hills Resources CFA, IIc gladstone companies IVRHA Sorenson Impact Institute

Mark Delphine Karla Ser-Chen CA Sathish Kumar Patricia William Carla Sajol Gregory Veronica Anthony David D. Jeremiah Genrev Robert Eric Arusha Stephen Josh Yoav Richard John Kristin Weiging Amadou Bobby Joan Bernadette Annabella Gutman Marjorie Mark Fizie Alberto Steve Malcolm Chris Shiori Qaizar Sibylle Arthur Teresa Bill Reece Reece Browning Madeline Lihong Eddie Elena CJ Dalibor Mollie Laura Sunhee Tomohiro Hippler Vincent Randolph Veronica Mike Paul Mabs Tom Cody Jessica Dave PR Mahari Laksh Xin Shan Carl Kevin Carl

Fling Fouque Francisco Gallagher Galle Garcia Ghoshal Giammittorio Gibaja Gilliam Gladstone Gladstone Gonzaga Goodman Gottlieb Goyal Green Greenberg Greenberg Greene Gregg Gross Gu Gueye Gupta Gutierrez Gutman Guzman Haas Haleem Halfeld Hamrick Handelsman Harrises Hasegawa Hassoniee Hauser Henderson Henning Henry Herberg Herberg Herbert Hewatt Hicken Hill Hinderliter Hinshaw Hodko Holter Hong Hong Hosono Houda Hovorka Hubbell Hurtado Huska lacovacci Imala Irby Isabel lves Izuka Jackson Jackson Jain Jiang Jin Jones Jones Jones

Fu

G

Founder / Senior Consultant Travel App Consultant Director Partner Associates Principal President CEO. Founder CEO Partner Senior Director Owner CEO CEO Strategic Advisor President Founder Founder President Principal Consultant Consultant Advisor CEO CEO Founder CEO CEO Co Founder & CEO Virtual Assistant CEO CEO CEO **Business Solutions Manager** Associate Senior Attorney ED President Associate Managing Partner SVP, Corporate Development & Strategy CEO Director CEO Marketing Admin Enterprise Accounts Manager Managing Director **Business Operations Manager** CEO Director, Mason Enterprise Center Entrepreneur Investor CEO President and Founder CEO Managing Partner CEO CEO Public Speaker CEO **Business Development Consultant** Chief Technology Officer CIO Director CEO CEO and Founder CAO Venture Accelerator Founder Analyst CO0 Co-founder and VP Director Managing Partner CEO Managing Partner

Tech Infinity Consulting TRAVEL ADVANTAGE **TOPAZ Clinical Research** Pacific 8 Ventures SBSS & Associates Treasury Solutions Info Tech LLC DPS MyPlanKeeper.ai Advanced TeleSensors Inc. Potomac Law Group PLLC Redona Tx Calcio Business Solutions gladstonecompanies SafeQual Nexus **Technical Interviewers** Modo Melius Initiative Goyal Consulting Group, Inc Transradial Technologies. Inc. Astral Partners International Astral Partners International **RGA Venture Funding** BalinBac Therapeutics, Inc. Navdee Data-to-Decision Dasion Corporation TANIM Votal AI Inc. **Royal Belle Equity Partners** Club Annabella Corp **TOPAZ** Clinical Research AEG Montgomery College Draper Associates Trow & Rahal, P.C. DIR Technical Solutions, Inc. Vision Platform Angel Star Ventures Open Biopharma Research & Training Institute Affinity Networks, Inc. moneymasternow Gander OptfinITy Leatt USA **Ringbolt** Capital Zenus, Inc. Theysaid George Mason University **Bootstrap Venture Partners** Nexogen, Inc. MicroBio Consulting AlaCura LINKORUS DataSpring HB Engineering Vincent Coach Ltd Transradial Technologies, Inc PEO Canada Vistra Business Solutions **Enascor** Capital ATCC Skribe.ai Mind, Brain, Body Lab Renaissance Venture Capital Venture Acceleration and Incubation Services STORC KLS Alliance Cleanto Protego Biopharma Genytix Inhite Ventures Med Trusted Business Advisors

Paul к Olga К Alan Kadish Shoshi Kaganovsky Vinu Kalla Ron Kazel Martine Keenan Alan Kersey Joe Kessler Gene Kim Uchenna Kingsley Dr Ted Kirsch Ted Koblick Martin Koev Muhammed Shukkoor Kondengaden Velibor Koprivica Adam Koster Nick Kovacic Arina Kozyr Victoria Kozyreva John Krawczyk John Krawczyk Kreisberg Jason Rishu Kumar Sachin Kumar Nikhil Kumtha Kurnik Brenda Sowmyanarayanan L Alin Lacea Norman Lai Joanne Lancaster Kevin Lancaster Tony Lau Lazaridis Nick Bob Leach LeBow Ines Marcus Lee Tim Lee Jack Lee Juliette Lelievre Basile Lemba Joe Lemon Bertrand Leseigneur Don Lin Roh Link Kaylin Lo Tripti Lochan Francis Long Emith Lopez Harlan Lovestone George Luniv George Luniv Yevhenii Lytvynenko Jingsen Ma Madabushi Amrita Svetlana Makarova Josh Maldonado Aditya Malik Kevin Malloy Usman Mani Harrison Marick Subhi Marwari John Mattison Aditya Maurya Beth MB McColl Sean McEntvre Stacie Kevin McNulty McQuilliams Jeffrev Hetal Mehta Ofir Meir Ofir Meir Rayan Meliani Mendralla Robert

мн ITPM CEO CEO House wife Managing Member CO0 General Partner Managing Partner Founder **Business Development Manager** CEO Vice President of Business Development Manager Founder Chief Strategy Officer CEO Partner Senior Director Business Development Venture Associate President Investor and advisor Associate Director Bachelor of engineering СТО Director Angel Investor Founder Tech Consultant BOD **VP** Clinical Development CEO Managing Director President **Business Advisor** CEO/Founder Managing Partner CISO Managing Director VC Analyst Founder and CEO Founder Director of Marketing Co-founder and CIO Founder & CEO Entrepreneur Director Director Vice President Director of Business Development Artist Founder / Director / System Engineer CEO VP Founder Founder Founder Founder & CEO сто Software developer **Chief Strategy Officer** Principal Scientist CMIO CEO FD ceo CEO Director President CEO сто President Founder & CEO President, Investments

Hainvur NoName InvestorMatch.ai RingOn Home Kalliam Capital LLC Anaxis Pharma Cycle Venture Partners Next-Stage Development Group LLC DragonStartups Lead Homes Luxury and Apartments CaperRX.Inc. Net-AV Koev Brothers Glycodepot.com Enfinia Growth Partners Interactome Biotherapeutics Inc DealMaker.tech BMI Go Global World Flow Simulations SafeQual Sanford Labs Chandigarh university Travelory Inc CliftonLarsonAllen LLP Robin hood ventures **Tescribe Consulting Services** USMedigene NGM Bio **Channel Program** Space Strategies AccuGenomics Inc Braintree Business Development Center Enterprise Transformation Solutions SID Partners U.S. YUZANA Marketing Integration Afi ventures The Networking Institute Shaping Community Otonomi Telesair, Inc. TCA Keiretsu Forum Premon Asia Innovative Research Aquillius Art Haus Project Alomega Inc. HABS Dynaflow, Inc. EmpowerBio Spark Change ProActive Performance LLC Valuematrix Lab Inc. U-Credit maniwebdev **Tiber Solutions** CRO ACP Zelox Entertainment Evoto MCC Couplet Care, Inc. U-Credit SafeQual Gainfront, Inc. Tropic Biosciences Venturesq LLC TheDefinitiveGuide **RM Enterprises**

Lily Andris Efe Paul Randi Randi Shyrice Joseph O. Charles Judy Akhyansh Max Mpho Jonathan Alicia John Tina Rov Panos Vuyile Qasim Kevin Natalia Pradeep Charles Charles Umer Matey Heather Rene Maren Paul Jessica Gareth Michael Siphephelo Taylor Randall Martin Anindya Singh Russell Ebube Bob Catalina Avodeii Kadia Robi Niswanth Bill Velimir George Dilan Michael Mhiel Tom Bianca Diana William Doug Rama Joel Leonora Josephine Julia Habib Andrei Soheil José Miguel Ron Joe Damoder Ronald Todd Zacharia Cara

Meng Merkulovs Miller Miller Miller Miller Mitchell Mjomba Mobbs Mod Mohapatra Mohr Molepo Moore Moran Morgan Moriarty Morris Moutafis Mthethwa Mueen Mullenex Mykhaylova Nagachandran Nahabedian Nahabedian Nawab Nedkov Neisworth Nel Nelson Nemirovsky Nett Newman Niggel Nkosi Noble Noval Nsanta Obi O'Bryan Ofili Oros Ortiz Davis Osho Ouellette Overson Ρ Pagels Pajic Parrish Patel Peck Peralta Perkins Petrignani Pignalosa Podd Poretz Potturu Price Quilalang Rahma Rahman Raibekas Raissi Ramírez Jaramillo Reck Reddix Reddy Redmer Repsher Ressaissi Reuner

CEO MD CEO VP President President Business Development, Associate Director CEO Founder and CEO Founder + CEO Founder Fundraising Team Manager Managing Director Director, Innovation and Entrepreneurship Managing Principal **Ops Manager** Partner Founder/CEO Managing Director CEO CEO & Co-Founder CEO CEO CEO President Chief Strategist President Icarus Developer Interim Executive Director Advisor CEO Board Member Managing Director **Business Development** Founder / CEO Ambassador Founder **Business Performance Advisor** founder CEO & President coo CEO **Director Research Operations** Founder Intern CEO CSO, Founder **Chief Evangelist** Founder & Chief Editor (EIC) Founder IRO Director Scouting & Partnering Associate Head of Strategic Partnering President Principal сто VP of Product Innovation Project Manager VP Co-founder Co-Founder and CEO CEO CEO Principal President and CEO Investor Managing Partner General Manager **Global Development Officer** Investment Team

CoCarting CFAW RODIA Advanced Clinical Venturesq LLC Flow Simulations Aragen Bioscience Fuli Africa Gilga-Med, Inc. Innovations Domain, LLC **Oxytocin Labs** Start Engine HLG Biopharmada PGCEDC Morgan Global Malloy Industries STI Zenus. Inc. Nyambose Corporation PTY Zigron iotaBEAM, Inc. WeavAir Suvarna Partners VK Digital Health Business Development Resources Inc. Ad Labz ICE VP of Marketing **Oxlyn Analytics** Alliance of Angels Advisorv Georgetown University in Qatar Plausible Gaming ACT1 Federal Phakiso Hlatshwayo Holdings Proudly Curiocity Company Connectpreneur Niiti Insperity habeet games Potomac Business Group Metadvising ROI NG Fosun Pharma USA Wood Alloy Serin Reliable-LFC, LLC Liquim Ltd. **Bay Angels** DIL Media LTD Fpabio Royal Belle Equity Blu Venture Investors Debiopharm Debiopharm International SA Landmark Family Office Doug Poretz LTD Vero Finance Technologies Core Source Technologies Zavod IT PayToMe.co DigiWorks Interspace Biosystems LLC Maptics Quantitec Derecho & TICS SAS RRECKTEK LLC The Reddix Group **Chemical Angels** R-Squared Capital Partners Group LLC Leatt Astrid Pharma World Fund

Alexander John Victors Kait Deja Andres Lindsey Adam Anne Robert Larry Larry Darlene Paul Nader Padmesh Eli Daurija Kathryn Amir Andrey Christian David Marthe Marthe Gabi Simone Gerhard Gerhard Gary Peter Gary Kristen Mahesh mahesh Dany Dany Mitesh Shaishav Stephen Peter Amir Fisnik Gary Edward Edward Monet Tarun Tom Stephen Yuvrai Grace Clarissa Michael Ernest Henry Mark Chloe Ning Hilary Tom Shunva Venkat Krishna Sasank Kevin Manquel Jayant Chris Bob J. Greg Tγ Sheena Matthew Fatemeh

Reynolds Rezaiyan Rhoder Rikkers Robinson Rocha Roddy Rogers Rosario Rosenberg Rosenfeld Rosenfeld Ross Ruppert S S Saad Sabaliauskiene Sabanos Saberi Sanenko Saravia Schaefer Schaper Schaper Schindler Schöpp Schwandt Schwandt Schwartz Schwartz Schwartz Seeley Seethagari seethagari Sfeir Sfeir Shah Shah Shambaugh Shih Shiner Shpuza Shultz Sigmond Sigmond Simpson Singh Solitario Son Sonal Song Sowemimo-Coker Spector Stern Stoever Sullivan Sun Sung Sutton Swanson Tachibana Tadakamalla Talasila Taylor Tejeda Thatte Thomas Thorssen Tinch Tioelker Toma Tompkins Tonimoghadam

Owner / Talent Acquisition Partner Advisor/Coach/Mentor VP of Channels and Strategic Partnerships Cofounder/COO Medical Device Reviewer Director of Global Ops Chief Executive Officer CEO CEO President Co-Founder CEO CFO President Founder IT Partnerships CTO & Co-founder Product Manager Scientific Director Head of Delivery CEO Attorney Attorney СМО Director Finance Certified Executive Coach + Executive Business Coach + CFO President CEO смо **Innovation Specialist** Marketing Administrator CEO CEO Founder Founder Founder CEO CEO Founder/CEO Innovation Specilist President President Beauty Instructor CFO Technology Scout Product Marketing Consultant BOD CEO CEO Founder Partner Managing Partner Managing Director SVP Investor Founder President Investment Partner President Cofounder and Chief information officer **VP Client Success** Co-Founder Founder and CEO Fractional CFO / Consultant Co-Chair Deal Flow Principal Director Nurse Practitioner Founder Founder and CEO

Hippogriff Consulting LLC **3E Consulting LLC** AtWork Systems LLC Pliable FDA EDX RoddyMedical Inc. Hemera Biosciences **Top Virtual Assistants** SMC Tysons Angel Group VK Digital Health Dees Unlimited, LLC GPV Ltd. genex IT General Assembly MB Exportas WeVideo Vita Tx VReal Soft CORP Phoreus Biotechnology Studio Legal Studio Legak Cota Capital peppermint Gerhard B Schwandt Gerhard B. Schwandt HedoniaUSA, Inc Jibe Consultants HedoniaUSA. Inc Kagency Ziva Consulting OptfinITy HedoniaUSA, Inc HedoniaUSA Inc. video-animation-service.com Softvan Group Purity Digital Vizaport RepAir Carbon zerapy.ai Ziva Consulting American Business Network American Business Network WantMoStyles LLC CIPHER CAPITAL Tom. Inc. / Maximus Ventures Independent Taxanomic Goldway International, LLC Oxford Cannabinoid Technologies Champlain Bio Culhane PLLC Windsor Strategy **Big Sky Medical** Buckman Buckman & Reid Sand Hill Angels HSL Digital TJSwanson Co. Joyance Partners **ITSYS** Inc Stayflexi zerapy.ai 1A Robotics Turiya Therapeutics LLC Blue Oak Consulting LLC **Bay Angels** Tinch Law Firm P.C. gener8tor IB Curiate Robo Lodge LLC

Phong Vishwa Stefanie Lekzin Mike Carol Chris srihari Roy Ilya Jeff Varun P Elle Jim Michelle S Eric Jordan Kim Perliter Sydney Kyoko Joshua Peter Barry Robert Andrew Joseph Earl Laurie Norelle Alan Wilbert Donald Rob James Kristine Amy Guoqiang Guoqiang Jiahui Yi Zhaohui Ricky Punnapa Fbru Susan Susan Jonathan Erica Raymond Raymond Raymond Juliet

Tran Trivedi Trop Tshering Ulker Vancleef Veator vedartham Vella Vensky Vigil Vishal Vitin Voeller Vos Wachtel Wahbeh Wales Walters-Gilliam Warren Watanabe Weaver Weber Weinbaum Weissman Wert Whang White Wiggins Wildburger Willey Williams Williams Williamson Wilson Wilson Wood Xing Xing Xu Yang Yang Yang Yannarat Yildirim Young Young Zaikowski Zhang Zoeller Zoeller Zoeller Zon

CEO Senior Associate Director, Life Sciences Data Science VP CEO Investor Head M&A Managing Director General Partner President Founder Founder / CEO Patent Attorney Managing Partner CEO Managing Partner Chief Executive Officer President Founder and CEO Managing Director IT Consultant Consultant **Financial Services Professional** President President Consultant President & CEO CEO CEO CEO Federal Business Development Growth Strategist Investment Advisor Co-Founder Chairman Founder Program Manager CEO CEO TPM Managing Partner Senior Advisor Officer Founder Founder Principal CEO & President Assistant Director Co-Founder Investor and Advisor Investor and Advisor

Life Sciences Consultant

SirnaMed Therapeutics Inc. **Zynext Ventures** Maryland Department of Commerce NRC PayToMe.co LG Avion Vella Ventures Provision Ventures My Business Matches, Inc Yajna Ventures LVitin Maier & Maier Inhite Ventures SmartMD Systems Inc. SV Venture Group CrowdBureau Corp Nuts & Bolts Business Enterprises OXY-TECH, INC. **DEFTA** Partners Ctrl Shift LLC SolasAI New York Life Suvarna Partners LLC CertAir Deloitte MDx BioAnalytical Laboratory, Inc. Byond Nanost Noxsano Inc. Self-employed Prime Capital Financial ShipThrifty.com Zea Biosciences KOMYOON Pepperdine University Lotus Biotech.com LLC Lotus Biotech.com LLC Georgetown WaterStar Capital **Prevail Therapeutics** Cincowel 52 CoffeeHouse Ollang Blue Dog Consulting LLC Potomac Business Group New York Angels 52 CoffeeHouse

Johns Hopkins University

SafeQual

K2X Technology and Life Science Inc.

THANK YOU TO OUR PREP TEAM



LAURA HILL SVP Equifi



INES LEBOW CEO Enterprise Transformation Solutions



MARISSA LEVIN CEO Successful Culture International



BOB LONDON CEO Chief Listening Officers



JET LU Customer Solutions Amazon Web Services



JACKIE LUO Founder BAM Advisory



MICHELLE MILLER Founder MRM Consulting



JOHN MORGAN General Partner Morgan Global



EVAN SHUBIN Pres. and Founder Results.now, Inc. and Candlelight Partners



MALI PHONPADITH CEO SOAR Community Network



MICHAEL RIEMER CEO & Board Member Vocinity

SPONSORS















Entrepreneurs` Organization



KEIRETSU













Angels + Life.Sci Investors

THE CENTER FOR ADVANCING



ANNUAL

RTON DO



ROBERT H. SMITH

DINGMAN CENTER for ENTREPRENEURSHIP





WANT TO PRESENT OR SPONSOR At our virtual events?

Email Skylar Rallison at srallison@opus8.com for more information

2024 Virtual Calendar

Aug. 29	Oct. 31
Nov. 21	Dec. 19

REGISTER FOR OUR UPCOMING EVENTS

<u>August 8</u> <u>In-Person</u>



<u>August 29</u> <u>Virtual Pitch</u>



<u>September 19</u>





CONNECT WITH US!



CUSTOM PRIVATE INVESTOR MEETING

Overview

- Opus8 manages one of the world's largest investor communities with 4,000+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.
- We have become a reliable curator and source of high-quality investment opportunities for this community.
- The Client is the exclusive host of these private investor meetings. No other competing or external entities in the meeting.
- Opus8 will screen a minimum of 20+ pre-qualified attendees for the event. The general attendee mix is 75% investors and 25% COIs (Centers of Influence).
- Attendee/RSVP lists with contact information and LinkedIn profiles and other data will be provided to the Client before and after the event.

Check out the full brochure with all information here:



Our 9-Step Process

1. Review investment materials and determine key investment considerations.

2. Develop a list of potential investors.

3. Create a "teaser invitation" and send it to investor candidates along with an executive summary

4. Confirm and vet RSVPs

5. Answer any questions or info requests pre-event.

6. Triple confirm all RSVPs via email and calendar invitations.

7. Host the private investor event and follow-up with attendees.

8. Introduce any RSVPs who did not attend to management.

9. Assist in following up with any and all investor prospects post-event.